Patents by Inventor Stanley V. D'Andrea

Stanley V. D'Andrea has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20020049191
    Abstract: The present invention provides a novel series of cephem derivatives of the general formula I 1
    Type: Application
    Filed: May 29, 2001
    Publication date: April 25, 2002
    Inventors: Dane M. Springer, Bing Y. Luh, Stanley V. D'Andrea, Thomas W. Hudyma, Oak K. Kim
  • Patent number: 6265394
    Abstract: Provided by the present invention are cephem derivatives represented by the general formula wherein Ar is an optionally substituted lipophilic phenyl, naphthyl or pyridyl group; L1 and L2 are (C1-C6)alkylene optionally substituted with hydroxy or oxo and/or optionally interrupted with a vinylene group, S, O, aryl, heteroaryl, in which R1 is H or (C1-C6)alkyl; A is CO2H, PO3H, SO3H, tetrazolyl or x′{circle around (−)} is a pharmaceutically acceptable anion; and Q is an quaternized nitrogen group. The derivatives are gram-positive antibacterial agents especially useful in the treatment of diseases caused by methicillin-resistant Staphylococcus aureus.
    Type: Grant
    Filed: August 4, 1999
    Date of Patent: July 24, 2001
    Assignee: Bristol-Myers Squibb Company
    Inventors: Roman Z. Sterzycki, Oak K. Kim, Yasutsugu Ueda, Stanley V. D'Andrea, Dane M. Springer
  • Patent number: 6093712
    Abstract: Provided are cephem derivatives represented by the general formula ##STR1## wherein Ar, R.sup.1, R.sup.2, R.sup.3, R.sup.9 and R.sup.10 are as defined in the application. The derivatives are gram-positive antibacterial agents especially useful in the treatment of diseases caused by methicillin-resistant Staphylococcus aureus.
    Type: Grant
    Filed: December 10, 1998
    Date of Patent: July 25, 2000
    Assignee: Bristol-Meyers Squibb Company
    Inventors: John D. Matiskella, Stanley V. D'Andrea, Thomas W. Hudyma, Yasutsugu Ueda, Oak K. Kim, Raymond F. Miller, Shelley E. Hoeft, Joanne J. Bronson
  • Patent number: 5668284
    Abstract: Novel cephem derivatives represented by the general formula ##STR1## in which the Acyl substituent is a group of the formula ##STR2## wherein Ar is a lipophilic optionally substituted phenyl, naphthyl, pyridyl or benzthiazolyl group; R.sup.1 is selected from certain optionally substituted aliphatic, aromatic, arylaliphatic or sugar moieties and R.sup.2 and R.sup.3 are each independently hydrogen, alkyl or aminoalkylcarbonylamino are gram-positive antibacterial agents, especially useful in the treatment of infectious diseases caused by methicillin-resistant Staphylococcus aureus (MRSA).
    Type: Grant
    Filed: May 8, 1996
    Date of Patent: September 16, 1997
    Assignee: Bristol-Myers Squibb Company
    Inventors: Choung U. Kim, Peter F. Misco, Jr., John A. Wichtowski, Yasutsugu Ueda, Thomas W. Hudyma, John D. Matiskella, Stanley V. D'Andrea, Shelley E. Hoeft, Raymond F. Miller, Muzammil M. Mansuri, Joanne J. Bronson
  • Patent number: 5668290
    Abstract: Novel cephem derivatives represented by the general formula ##STR1## in which the Acyl substituent is a group of the formula ##STR2## wherein Ar is a lipophilic optionally substituted phenyl, naphthyl or pyridyl group; R.sup.1 represents either the residue of a heterocyclic amino acid or a C.sub.2 -C.sub.10 alkyl group substituted by both a carboxyl group and a group of the formula --NR.sup.9 R.sup.10 or ##STR3## in which R.sup.9 and R.sup.10 are each independently hydrogen or C.sub.1 -C.sub.6 alkyl, said C.sub.2 -C.sub.10 alkyl group being optionally interrupted by one or more nitrogen atoms or carbonyl groups, and R.sup.2 and R.sup.3 are each independently hydrogen, alkyl or aminoalkyl are gram-positive antibacterial agents, especially useful in the treatment of diseases caused by methicillin-resistant Staphylococcus aureus (also referred to below as MRSA or methicillin-resistant S. aureus).
    Type: Grant
    Filed: August 23, 1996
    Date of Patent: September 16, 1997
    Assignee: Bristol-Myers Squibb Company
    Inventors: Joanne J. Bronson, Stanley V. D'Andrea, Shelley E. Hoeft, John D. Matiskella, Peter F. Misco, Jr., Bing Yu Luh, Dane M. Springer, Yasutsugu Ueda, John A. Wichtowski
  • Patent number: 5620969
    Abstract: Novel cephem derivatives represented by the general formula ##STR1## in which the Acyl substituent is a group of the formula ##STR2## wherein Ar is a lipophilic optionally substituted phenyl, naphthyl or pyridyl group; R.sup.1 represents either the residue of a heterocyclic amino acid or a C.sub.2 -C.sub.10 alkyl group substituted by both a carboxyl group and a group of the formula --NR.sup.9 R.sup.10 or ##STR3## in which R.sup.9 and R.sup.10 are each independently hydrogen or C.sub.1 -C.sub.6 alkyl, said C.sub.2 -C.sub.10 alkyl group being optionally interrupted by one or more nitrogen atoms or carbonyl groups, and R.sup.2 and R.sup.3 are each independently hydrogen, alkyl or aminoalkyl are gram-positive antibacterial agents, especially useful in the treatment of diseases caused by methicillin-resistant Staphylococcus aureus (also referred to below as MRSA or methicillin-resistant S. aureus).
    Type: Grant
    Filed: April 25, 1995
    Date of Patent: April 15, 1997
    Assignee: Bristol-Myers Squibb Company
    Inventors: Joanne J. Bronson, Stanley V. D'Andrea, Shelley E. Hoeft, John D. Matiskella, Peter F. Misco, Jr., Bing Y. Luh, Dane M. Springer, Yasutsugu Ueda, John A. Wichtowski
  • Patent number: 5567698
    Abstract: Novel cephem derivatives represented by the general formula ##STR1## in which the Acyl substituent is a group of the formula ##STR2## wherein Ar is a lipophilic optionally substituted phenyl, naphthyl, pyridyl or benzthiazolyl group; R.sup.1 is selected from certain optionally substituted aliphatic, aromatic, arylaliphatic or sugar moieties and R.sup.2 and R.sup.3 are each independently hydrogen, alkyl or aminoalkylcarbonylamino are gram-positive antibacterial agents, especially useful in the treatment of infectious diseases caused by methicillin-resistant Staphylococcus aureus (MRSA).
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: October 22, 1996
    Assignee: Bristol-Myers Squibb Company
    Inventors: Choung U. Kim, Peter F. Misco, Jr., John A. Wichtowski, Yasutsugu Ueda, Thomas W. Hudyma, John D. Matiskella, Stanley V. D'Andrea, Shelley E. Hoeft, Raymond F. Miller, Muzammil M. Mansuri, Joanne J. Bronson
  • Patent number: 5559108
    Abstract: Novel cephem derivatives represented by the general formula ##STR1## in which the Acyl substituent is a group of the formula ##STR2## where Ar is a substituted phenyl or optionally substituted naphthyl or benzthiazolyl group and A is a substituted-pyridinium group are gram-positive antibiotics, especially useful in the treatment of diseases caused by methicillin-resistant Staphylococcus aureus.
    Type: Grant
    Filed: May 22, 1995
    Date of Patent: September 24, 1996
    Assignee: Bristol-Myers Squibb Company
    Inventors: Choung U. Kim, Muzammil M. Mansuri, Peter F. Misco, Jr., John A. Wichtowski, Joanne J. Bronson, Stanley V. D'Andrea, Thomas W. Hudyma
  • Patent number: 5436369
    Abstract: Certain novel alicyclic compounds are effective phospholipase A.sub.2 (PLA.sub.2) inhibitors.
    Type: Grant
    Filed: February 23, 1994
    Date of Patent: July 25, 1995
    Assignee: Bristol-Myers Squibb Company
    Inventors: Joanne J. Bronson, Katharine M. Greene, Muzammil M. Mansuri, Stanley V. D'Andrea, F. Ivy Carroll, Anita Lewin